US FDA approved new drug Vosevi that contains combination of drug as a fixed dose for the treatment of chronic hepatitis C without cirrhosis or with mild cirhosis.Vosevi contains 3 kind of drugs that include sofosbuvir in 400mg strength which is NS5B inhibitor, Velpatasvir in 100mg which is NS5A inhibitor and voxilaprevir in 100mg strength which is NS3/4A inhibitor. Vosevi is administered as once daily dose of combined therapy (fixed dose).
Hepatitis C is a viral infection caused by virus family Flaviviridae. Hepatitis C virus is single stranded RNA virus with seven genotypes starting from 1 to 7. Most commonly occurring genotypes are 1,2,3 and 4. At early stages patient have no or insignificant symptoms like mild pain in abdomen,
mild fever, dark urine and yellowish tinged color skin.
Hepatitis C virus spreads via blood to blood contact in the form of contaminated syringes, razors, needles, nail cutters, tooth brush, piercing equipment etc. Blood transfusion (contaminated blood) is another way of transferring HCV from one person to another. Vertical transmission is also possible in case of hepatitis C for example it can spread through an infected mother to her baby during birth.
Unfortunately, patient feels no symptoms at early stages and when diseases enters into progressive stage it becomes difficult to treat. So far, there is no vaccine for hepatitis c due to diversity in genotype of hepatitis c virus. In later stages, symptoms become more prominent like loss of appetite,
fatigue, nausea, muscle weakness, fever, blood in vomit and stool. At cirrhosis stage liver becomes inflamed and it causes internal hemorrhaging, portal hypertension and ascites.
During clinical trails Vosevi showed promising results. Those patients who were taking Vosevi had no virus in their blood after 12 weeks of therapy. During clinical trails this drug decrease viral load effectively in variety of patients having genotype one to six.
Vosevi Side effects
According to health authorities Vosevi exhibit following side effects during clinical trials
- Mild fever
- Abdominal Bloating
- Muscular pain
Vosevi Uses/Patient information
US FDA indicated this drug for the treatment of chronic hepatitis C without cirrhosis or with mild cirrhosis in adults patients having virus genotype 1-6. Patient taking rifampin must not be used this drug because it usage is contraindicated during rifampin therapy.
Vosevi contains 3 kind of drugs that include sofosbuvir in 400mg strength which is NS5B inhibitor, Velpatasvir in 100mg which is NS5A inhibitor and voxilaprevir in 100mg strength which is NS3/4A inhibitor. Vosevi is administered as once daily dose of combined therapy (fixed dose).